Related Experiment Video

Updated: Aug 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Rho-kinase inhibition in the therapy of cardiovascular disease

Andrew Lai1, William H Frishman

  • 1Department of Medicine, Kaiser Permanente/Los Angeles Medical Center, Placentia, NY 10595, USA.

Cardiology in Review
|October 19, 2005
PubMed

Insights

Rho-kinase plays a key role in cardiovascular disease by mediating smooth muscle contraction. Inhibiting Rho-kinase shows promise for treating conditions like hypertension and heart failure.

Area of Science:

  • Molecular Biology
  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Rho GTPase is a critical regulator of cell structure and function, including smooth muscle contraction.
  • Rho-kinase activity is implicated in cardiovascular diseases, particularly those involving vascular smooth muscle dysfunction.
  • Recent characterization highlights Rho-kinase's role in calcium sensitization during vascular smooth muscle contraction.

Purpose of the Study:

  • To explore the role of Rho-kinase in cardiovascular disease pathogenesis.
  • To investigate the therapeutic potential of Rho-kinase inhibitors in cardiovascular conditions.

Main Methods:

  • Review of existing literature on Rho GTPase and Rho-kinase.
  • Analysis of clinical trial data for Rho-kinase inhibitors (fasudil, Y-27632).
  • Examination of Rho-kinase's role in calcium sensitization and vasoconstriction.

Main Results:

  • Increased Rho-kinase activity contributes to vasoconstriction in conditions like hypertension and myocardial ischemia.
  • Rho-kinase inhibitors demonstrate anti-ischemic, antivasospastic, and antihypertensive effects in clinical trials.
  • These inhibitors also show potential in mitigating cardiomyocyte hypertrophy and cardiac remodeling in heart failure.

Conclusions:

  • Rho-kinase is a significant mediator in cardiovascular pathophysiology.
  • Inhibition of Rho-kinase represents a promising therapeutic strategy for various cardiovascular diseases.
  • Targeting Rho-kinase offers a novel approach for cardiovascular disease treatment.

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...